Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.87 [0.66, 1.14] | | < 1 | | 0% | 1 study (1/-) | 84.1 % | NA | not evaluable | | crucial | - |
MFS | 0.73 [0.56, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.8 % | NA | not evaluable | | important | - |
RFS (extension) | 0.71 [0.59, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
RFS/DFS | 0.65 [0.51, 0.83] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
safety endpoints 00 |
AE (any grade) | 0.49 [0.20, 1.23] | | < 1 | | 0% | 1 study (1/-) | 93.6 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 0.28 [0.21, 0.37] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 0.15 [0.10, 0.21] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 0.11 [0.07, 0.18] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.25 [0.15, 0.43] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) | 0.20 [0.14, 0.27] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to death (grade 5) | 0.25 [0.01, 5.55] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (any grade) | 0.12 [0.08, 0.17] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE leading to discontinuation (grade 3-4) | 0.09 [0.05, 0.15] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Abdominal pain TRAE (grade 3-4) | 0.50 [0.02, 14.96] | | < 1 | | 0% | 1 study (1/-) | 65.3 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 0.50 [0.09, 2.74] | | < 1 | | 0% | 1 study (1/-) | 78.7 % | NA | not evaluable | | non important | - |
Arthralgia TRAE (grade 3-4) | 0.50 [0.05, 5.53] | | < 1 | | 0% | 1 study (1/-) | 71.3 % | NA | not evaluable | | non important | - |
Asthenia TRAE (grade 3-4) | 0.25 [0.03, 2.24] | | < 1 | | 0% | 1 study (1/-) | 89.1 % | NA | not evaluable | | non important | - |
Diabetes TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 0.15 [0.07, 0.34] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.50 [0.09, 2.74] | | < 1 | | 0% | 1 study (1/-) | 78.7 % | NA | not evaluable | | non important | - |
Gastrointestinal disorders TRAE (grade 3-4) | 0.10 [0.05, 0.20] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Headache TRAE (grade 3-4) | 0.14 [0.02, 1.15] | | < 1 | | 0% | 1 study (1/-) | 96.5 % | NA | not evaluable | | non important | - |
Hepatobiliary disorders TRAE (grade 3-4) | 0.15 [0.07, 0.32] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Hypersensitivity TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.00 [0.06, 16.07] | | < 1 | | 0% | 1 study (1/-) | 49.9 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 0.18 [0.04, 0.81] | | < 1 | | 0% | 1 study (1/-) | 98.7 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 0.50 [0.05, 5.53] | | < 1 | | 0% | 1 study (1/-) | 71.3 % | NA | not evaluable | | non important | - |
Increase AST TRAE (grade 3-4) | 0.10 [0.02, 0.44] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.18 [0.07, 0.48] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 0.05 [0.00, 0.95] | | < 1 | | 0% | 1 study (1/-) | 97.6 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 2.01 [0.07, 59.97] | | < 1 | | 0% | 1 study (1/-) | 34.6 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.10 [0.01, 1.82] | | < 1 | | 0% | 1 study (1/-) | 93.8 % | NA | not evaluable | | non important | - |
Pyrexia TRAE (grade 3-4) | 0.25 [0.01, 5.55] | | < 1 | | 0% | 1 study (1/-) | 80.7 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.35 [0.13, 0.98] | | < 1 | | 0% | 1 study (1/-) | 97.7 % | NA | not evaluable | | non important | - |
Renal and urinary disorders TRAE (grade 3-4) | 1.00 [0.02, 50.62] | | < 1 | | 0% | 1 study (1/-) | 50.0 % | NA | not evaluable | | non important | - |
Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 0.12 [0.01, 2.36] | | < 1 | | 0% | 1 study (1/-) | 91.5 % | NA | not evaluable | | non important | - |
Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.18 [0.07, 0.46] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |